RxDoctor Payments Data

Ashley Marcus, MD

Physical Medicine & Rehabilitation · Brooklyn, NYNPI 1710248430

Payments from drug & device makers

$2,388in general payments, 2019–2025

Across 33 payments — averaging $72.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$908
  • Boston Scientific$901
  • AbbVie$256
  • Fidia Pharma USA Inc.$167
  • AstraZeneca$122
  • Pacira Therapeutics, Inc.$36

What the payments were for

  • Travel & lodging$52322%
  • Food & beverage$1,86578%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nevro Corp.8$908
Boston Scientific7$901
AbbVie(2 entities)6$256
Fidia Pharma USA Inc.9$167
AstraZeneca1$122
Pacira Therapeutics, Inc.2$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,388 in reported general payments places this provider in the 85th percentile of 872 physical medicine & rehabilitation providers in New York.

See all physical medicine & rehabilitation providers in New York

Medicare billing

Part B allowed, 2024
$152,663
Medicare patients
165
Services billed
1,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant12$12,270
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen84$2,844
Diclofenac Sodium106$1,649
Lidocaine23$1,566
Pregabalin58$1,249
Gabapentin108$991
Celecoxib64$674
Tizanidine Hcl57$629
Cyclobenzaprine Hcl84$564
Tramadol Hcl49$419
Amitriptyline Hcl52$407
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$375
Oxycodone Hcl14$277
Ibuprofen24$247
Baclofen12$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$256$12,27012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 872 physical medicine & rehabilitation providers in New York.

Other physical medicine & rehabilitation in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →